Who are Acelex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loqoa, Nevanac, Xibrom, Xapit, Valecoxib, Mobic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/polmacoxib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Acelex — Competitive Intelligence Brief

Acelex (POLMACOXIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Prostaglandin G/H synthase 2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Acelex (POLMACOXIB) — CrystalGenomics.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acelex TARGET	POLMACOXIB	CrystalGenomics	marketed		Prostaglandin G/H synthase 2
Loqoa	ESFLURBIPROFEN	Taisho Pharmaceutical Co., Ltd.	marketed		Prostaglandin G/H synthase 2	2015-01-01
Nevanac	NEPAFENAC	Harrow Health	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
Xibrom	BROMFENAC	Bausch Health	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
Xapit	PARECOXIB		marketed	parecoxib	Prostaglandin G/H synthase 2	2002-01-01
Valecoxib	VALDECOXIB		marketed	valdecoxib	Prostaglandin G/H synthase 2	2001-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-05-26 — Mobic · 10709713 · Method of Use · US
2030-05-26 — Mobic · 9974746 · Formulation · US
2030-05-26 — Mobic · 11253478 · Formulation · US
2030-08-31 — Mobic · 8545879 · Formulation · US
2033-03-31 — Mobic · 9526734 · Formulation · US
2035-03-31 — Mobic · 9808468 · Method of Use · US
2035-03-31 — Mobic · 9649318 · Formulation · US
2039-03-08 — Mobic · 11458145 · Method of Use · US
2039-03-08 — Mobic · 10881663 · Method of Use · US
2040-07-19 — Mobic · 12059423 · Compound · US
2041-07-31 — Mobic · 12263176 · Formulation · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acelex — Competitive Intelligence Brief. https://druglandscape.com/ci/polmacoxib. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab